Cover Image
市場調查報告書

OpportunityAnalyzer:膀胱癌 - 機會分析與預測

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025

出版商 GlobalData 商品編碼 293248
出版日期 內容資訊 英文 229 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:膀胱癌 - 機會分析與預測 OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025
出版日期: 2017年04月05日 內容資訊: 英文 229 Pages
簡介

主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的膀胱癌的治療藥市場,預計2015年∼2025年以12.5%的年複合成長率(CAGR)成長。

本報告提供膀胱癌的治療藥市場相關調查分析,疾病概要,流行病學,目前治療選項,未滿足需求和機會,研究開發策略,開發平台評估等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 疾病概要

  • 病因與病情生理
  • 分類/分期
  • 症狀
  • 預後
  • QOL

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 膀胱癌的流行病學預測
    • 確診的發病數量
    • 確診的發病數量 (各年齡)
    • 確診的發病數量 (性別)
    • 確診的發病數量 (年齡標準化) 等
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 目前治療選項

  • 概要
  • 診斷和治療
  • 臨床診療
  • 產品簡介:領導品牌,免疫療法
  • 產品簡介:領導品牌,化療

第6章 未滿足需求評估與機會分析

  • 概要
  • BCG復發性/難治性NMIBC患者的治療的改善
  • NMIBC患者的預防病情惡化
  • 重病的治療 (超過免疫查核點抑制劑)
  • 預測生物標記促進藥物研發
  • 診斷方法的改善

第7章 研究開發 (R&D) 策略

  • 概要
  • 臨床試驗設計

第8章 開發平台評估

  • 概要
  • 臨床實驗階段的有前途藥物
  • 初期階段的創新的方法

第9章 開發平台評估分析

  • 主要開發平台藥物臨床基準
  • 主要開發平台藥物的商業基準
  • 競爭評估
  • 10年預測
    • 美國
    • EU5個國家
    • 日本

第10章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC067POA

Bladder cancer is a urologic malignancy arising primarily from epithelial cells lining the bladder. In the vast majority of cases (>90%), bladder cancer manifests as transitional (urothelial) cell carcinoma (TCC). The remaining cases manifest as squamous cell carcinoma, adenocarcinoma, and in rare instances, carcinosarcoma. Bladder cancer is classified under the International Classification of Diseases, Tenth Revision (ICD-10) code C67. It is the ninth most common cancer in men and women worldwide, with the highest recurrence rate of any malignancy.

It is estimated that the bladder cancer market in the 7MM was valued at $360M in 2015. This market includes sales of approved, branded therapies and those of off-label drugs. Of the countries/regions in the 7MM, the 5EU contributed 45% of sales, while the US and Japan contributed 39% and 16%, respectively. By 2025, it is expected that the bladder cancer market in the 7MM to reach $1.17B, tripling in size, at a Compound Annual Growth Rate (CAGR) of 12.5%.

In 2025, the US will contribute 49% of sales, while the 5EU and Japan will contribute 35% and 16%, respectively. During the forecast period, the US market is expected to grow the fastest, at a CAGR of 15.2%, owing to the earlier and more widespread usage of programmed cell death protein 1 (PD-1) modulators. The 5EU market will grow the slowest, at a CAGR of 9.5%, and the Japanese market will grow at a CAGR of 12.7%.

Major drivers of growth in the bladder cancer market in the 7MM during 2015-2025 are expected to be the following -

  • Immunotherapies, specifically PD-1 modulators, will see entry and/or increased incorporation into treatment algorithms.
  • The launch of IO + IO combination therapies will fuel sales growth due to the premium pricing of these combination regimens.
  • Increased incident cases of bladder cancer across the 7MM will increase the drug treatable patient population.
  • Introduction of pipeline agents CG-0070, Vicinium, and Cyramza will expand treatment options for bladder cancer patients.

Historically, the bladder cancer market has been highly generic, with BCG and chemotherapies dominating the landscape. However, with the launch of Tecentriq and the subsequent launches of other PD-1 modulators, the bladder cancer treatment algorithms are expected to change during the forecast period. Though these PD-1 modulators are expected to have a significant impact on the treatment of bladder cancer, the reality is that a majority of patients (estimated to be upwards of 70%) will not respond to these drugs. Thus, pharmaceutical companies are looking at various ways to expand the treatable patient population.

While big pharma companies are focused on "me-too" PD-1 modulators, smaller companies are developing drugs with novel mechanisms of action (MOAs). Cold Genesys, Eleven Biotherapeutics, and FKD Therapies Oy all have late-stage candidates in the NMIBC setting that have distinctive MOAs. GlobalData believes that the bladder cancer market is an attractive prospect for these companies due to the combination of a high level of unmet need and relatively low regulatory hurdles, which provides a suitable risk-reward balance for developers with limited financial resources.

The report "OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025" provides overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following -

  • Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Altor Bioscience, AstraZeneca, BioCancell, Bristol-Myers Squibb, Chugai, Cold Genesys, Eleven Biotherapeutics, Eli Lilly & Co., Endo Pharmaceuticals, Exelixis, FKD Therapies Oy, Immunomedics, MedImmune, Merck & Co., Merck KgAa, OncoGenex, Ono Pharmaceutical, Pfizer, Pierre Fabre Medicament, Roche.

Scope:

  • Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the bladder cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Bladder Cancer: Executive Summary

  • 2.1. Bladder Cancer Market in the 7MM Expected To Triple in Size From 2015 to 2025
  • 2.2. Big Pharma Focuses on Label Expansion, While Smaller Companies Focus on Developing Drugs with Novel Mechanisms of Action
  • 2.3. The Levels of Unmet Need Remain High Across Bladder Cancer Settings
  • 2.4. Pipeline Agents Will Reduce Unmet Need, but Opportunities Remain
  • 2.5. NMIBC Settings Are Not Expected to Change Significantly, While PD-1 Checkpoint Inhibitors Are Expected to Gain Stronghold in Advanced Disease Settings
  • 2.6. What Do Physicians Think?

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification or Staging Systems
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Relative Survival
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used Tables
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for Bladder Cancer (2015-2025)
    • 4.5.1. Diagnosed Incident Cases of Bladder Cancer
    • 4.5.2. Age-Specific Diagnosed Incident Cases of Bladder Cancer
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of Bladder Cancer
    • 4.5.4. Age-Standardized Diagnosed Incidence Rates of Bladder Cancer
    • 4.5.5. Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis
    • 4.5.6. Five-Year Diagnosed Prevalent Cases of Bladder Cancer
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Diagnosis and Treatment
    • 5.2.1. Diagnosis
    • 5.2.2. Treatment Guidelines and Leading Prescribed Drugs
  • 5.3. Clinical Practice
  • 5.4. Product Profiles - Major Brands, Immunotherapies
    • 5.4.1. Bacillus Calmette-Guerin (BCG)
    • 5.4.2. Tecentriq (atezolizumab)
    • 5.4.3. Opdivo (nivolumab)
  • 5.5. Product Profiles - Major Brands, Chemotherapies
    • 5.5.1. GemCis (gemcitabine/cisplatin)
    • 5.5.2. Mitomycin C
    • 5.5.3. Valstar (valrubicin)
    • 5.5.4. Javlor (vinflunine ditartrate)

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Improved Treatments for Patients with BCG-Relapsed/Refractory NMIBC
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Prevention of Disease Progression in Patients with NMIBC
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for Advanced Disease Beyond Immune Checkpoint Inhibitors
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Predictive Biomarkers to Drive Drug Discovery
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnostic Methods
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Drug Development by Small Pharmaceutical Companies
    • 7.1.2. Intravesical Approaches for NMIBC May Give Way to Systemic Approaches in the Future
    • 7.1.3. Identification of Prognostic Markers for PD-1 Checkpoint Inhibitors
    • 7.1.4. Conversion of PD-1 Checkpoint Inhibitor Nonresponders to Responders
  • 7.2. Clinical Trial Design
    • 7.2.1. Registrational Studies: Open-Label, Non-Comparative Trial Designs Still Prevalent
    • 7.2.2. Variability of Trial Endpoints in Both the NMIBC and Advanced Disease Settings

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. CG-0070
    • 8.2.2. Instiladrin (rAD-Interferon (IFN)/Syn3)
    • 8.2.3. Vicinium (oportuzumab monatox)
    • 8.2.4. Apatorsen
    • 8.2.5. Cyramza (ramucirumab)
    • 8.2.6. PD-1 Immune Checkpoint Inhibitors
  • 8.3. Innovative Early-Stage Approaches
    • 8.3.1. ALT-803
    • 8.3.2. Cometriq (cabozantinib)
    • 8.3.3. BC-819
    • 8.3.4. IMMU-132(sacituzumab govitecan)

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line 10-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Bladder Cancer Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Primary Research - KOLs Interviewed for this Report
    • 10.5.1. KOLs
  • 10.6. Primary Research - Prescriber Survey
  • 10.7. About the Authors
    • 10.7.1. Analyst
    • 10.7.2. Therapy Area Director
    • 10.7.3. Epidemiologist
    • 10.7.4. Managing Epidemiologist
    • 10.7.5. Global Director of Therapy Analysis and Epidemiology
    • 10.7.6. Global Head and EVP of Healthcare Operations and Strategy
  • 10.8. About GlobalData
  • 10.9. Contact Us
  • 10.10. Disclaimer

List of Tables

  • Table 1: Bladder Cancer: Key Metrics in the 7MM
  • Table 2: Bladder Cancer Staging System
  • Table 3: AJCC TNM Staging System for Bladder Cancer - Definitions of Stages
  • Table 4: Symptoms of Bladder Cancer
  • Table 5: Bladder Cancer Prognosis by Stage
  • Table 6: Bladder Cancer Risk Factors
  • Table 7: 5EU, Relative Survival of Bladder Cancer (%), Men and Women
  • Table 8: 7MM, Sources of Bladder Cancer Incidence Data
  • Table 9: 7MM, Sources of Bladder Cancer Stage at Diagnosis Data
  • Table 10: 7MM, Sources of Bladder Cancer Relative Survival Data
  • Table 11: 7MM, Diagnosed Incident Cases of Bladder Cancer, Ages ≥15 Years, Both Sexes, N, Select Years 2015-2025
  • Table 12: 7MM, Age-Specific Diagnosed Incident Cases of Bladder Cancer, Ages ≥15 Years, Both Sexes, N (Row %), 2015
  • Table 13: 7MM, Sex-Specific Diagnosed Incident Cases of Bladder Cancer, Ages ≥15 Years, N (Row %), 2015
  • Table 14: 7MM, Incident Cases of Bladder Cancer by Stage at Diagnosis, Ages ≥15 Years, Men and Women, N (Row %), 2015
  • Table 15: 7MM, Five-Year Diagnosed Prevalent Cases of Bladder Cancer, Ages ≥15 Years, Both Sexes, N, Select Years 2015-2025
  • Table 16: Treatment Guidelines for Bladder Cancer
  • Table 17: Leading Treatments for Bladder Cancer, 2015
  • Table 18: Product Profile - TICE BCG
  • Table 19: Efficacy of TICE BCG in CIS Bladder Cancer
  • Table 20: Efficacy of TICE BCG in Preventing Recurrence of Ta/T1 Bladder Cancer in the US
  • Table 21: Efficacy of TICE BCG in preventing recurrence of Ta/T1 bladder cancer in The Netherlands
  • Table 22: Safety of TICE BCG
  • Table 23: TICE BCG SWOT Analysis, 2016
  • Table 24: Product Profile - Tecentriq
  • Table 25: Efficacy of Tecentriq in Metastatic Bladder Cancer (Cohort 2 of IMvigor210)
  • Table 26: Efficacy of Tecentriq in First-line, Cisplatin-Ineligible, Metastatic Bladder Cancer (IMvigor210 Cohort 1)
  • Table 27: Safety of Tecentriq in Second-Line Metastatic Bladder Cancer (IMvigor210 Cohort 2)
  • Table 28: Safety of Tecentriq in First-Line, Cisplatin-Ineligible, Metastatic Bladder Cancer (IMvigor210 Cohort 1)
  • Table 29: Tecentriq SWOT Analysis, 2016
  • Table 30: Product Profile - Opdivo
  • Table 31: Efficacy of Opdivo in Second-Line Advanced Bladder Cancer
  • Table 32: Efficacy of Opdivo + Yervoy in Second-Line Advanced Bladder Cancer
  • Table 33: Safety of Opdivo in SecondLline Metastatic Bladder Cancer (CheckMate-275)
  • Table 34: Opdivo SWOT Analysis
  • Table 35: Product Profile - GemCis
  • Table 36: Efficacy of GemCis in the First-Line Metastatic Setting
  • Table 37: Safety of GemCis
  • Table 38: GemCis SWOT Analysis, 2016
  • Table 39: Product Profile - Mitomycin C
  • Table 40: Mitomycin C SWOT Analysis, 2016
  • Table 41: Product Profile - Valstar
  • Table 42: Efficacy of Valstar
  • Table 43: Safety of Valstar
  • Table 44: Valstar SWOT Analysis, 2016
  • Table 45: Product Profile - Javlor
  • Table 46: Efficacy of Javlor
  • Table 47: Safety of Javlor
  • Table 48: Javlor SWOT Analysis, 2016
  • Table 49: Unmet Needs in Bladder Cancer, 2016
  • Table 50: Clinical Trial Design of Key Registrational Trials in the NMIBC Setting
  • Table 51: Clinical Trial Design of Key Registrational Trials in the MIBC and Metastatic Settings
  • Table 52: Key Late-Stage Pipeline Agents for Bladder Cancer, 2016
  • Table 53: Product Profile - CG-0070
  • Table 54: Efficacy of CG-0070 (Phase I)
  • Table 55: Efficacy of CG-0070 (Phase II/III BOND trial)
  • Table 56: Safety of CG-0070
  • Table 57: CG-0070 SWOT Analysis
  • Table 58: Product Profile - Instiladrin
  • Table 59: Efficacy of Instiladrin (Phase II)
  • Table 60: Safety of CG-0070
  • Table 61: Instiladrin SWOT Analysis
  • Table 62: Product Profile - Vicinium
  • Table 63: Efficacy of Vicinium (Phase II)
  • Table 64: Safety of Vicinium
  • Table 65: Vicinium SWOT Analysis
  • Table 66: Product Profile - Apatorsen
  • Table 67: Efficacy of Apatorsen (Borealis-1 Trial)
  • Table 68: Safety of Apatorsen (Borealis-1 Trial)
  • Table 69: Apatorsen SWOT Analysis
  • Table 70: Product Profile - Cyramza
  • Table 71: Efficacy of Cyramza in Second-Line, Metastatic Bladder Cancer
  • Table 72: Safety of Cyramza in Combination with Docetaxel
  • Table 73: Cyramza SWOT Analysis
  • Table 74: Product Profile - Avelumab
  • Table 75: Efficacy of Avelumab (Phase 1b JAVELIN Solid Tumor)
  • Table 76: Safety of Avelumab
  • Table 77: Avelumab SWOT Analysis
  • Table 78: Product Profile - Durvalumab
  • Table 79: Efficacy of Durvalumab in Advanced BC (Bladder Cohort of Study 1108)
  • Table 80: Safety of Durvalumab (Bladder Cohort of Study 1108)
  • Table 81: Durvalumab SWOT Analysis
  • Table 82: Product Profile - Keytruda
  • Table 83: Efficacy of Keytruda in Second-Line, Metastatic Bladder Cancer (Phase III KEYNOTE-045)
  • Table 84: Efficacy of Keytruda in First-Line, Cisplatin-Ineligible Bladder Cancer (Phase II KEYNOTE-052)
  • Table 85: Safety of Keytruda in second-line treatment of advanced bladder cancer (Phase III KEYNOTE-045)
  • Table 86: Keytruda SWOT Analysis
  • Table 87: Innovative Early-Stage Approaches for Bladder Cancer, 2016
  • Table 88: Efficacy of BC-819
  • Table 89: Safety of BC-819
  • Table 90: Clinical Benchmark of Key Pipeline Drugs - NMIBC
  • Table 91: Clinical Benchmark of Key Pipeline Drugs - MIBC and Metastatic Disease
  • Table 92: Commercial Benchmark of Key Pipeline Drugs - NMIBC
  • Table 93: Commercial Benchmark of Key Pipeline Drugs - MIBC and Metastatic Disease
  • Table 94: Top-Line Sales Forecasts ($M) for Bladder Cancer, 2015-2025
  • Table 95: Key Events Impacting Sales for Bladder Cancer, 2015-2025
  • Table 96: Bladder Cancer Market - Global Drivers and Barriers, 2015?2025
  • Table 97: Sales Forecast ($M) for Bladder Cancer in the US, 2015-2025
  • Table 98: Sales Forecast ($M) for Bladder Cancer in the 5EU, 2015-2025
  • Table 99: Sales Forecast ($M) for Bladder Cancer in Japan, 2015-2025
  • Table 100: Key Historical and Projected Launch Dates for Bladder Cancer
  • Table 101: Key Historical and Projected Patent Expiry Dates for Bladder Cancer
  • Table 102: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Bladder Cancer by Country/Region, 2015 and 2025
  • Figure 2: Competitive Assessment of Marketed and Pipeline Agents in NMIBC, 2015-2025
  • Figure 3: Competitive Assessment of Marketed and Pipeline Agents in MIBC/Metastatic Disease, 2015-2025
  • Figure 4: Primary Tumor Development in Bladder Cancer
  • Figure 5: 7MM, Age-Adjusted Diagnosed Incidence Rates of Bladder Cancer (Cases per 100,000 Population), Ages ≥15 Years, Men, 1998-2007
  • Figure 6: 7MM, Incidence Rates of Bladder Cancer (Cases per 100,000 Population), Ages ≥15 Years, Women, 1998-2007
  • Figure 7: 7MM, Diagnosed Incident Cases of Bladder Cancer, Ages ≥15 Years, Both Sexes, N, Select Years 2015-2025
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Bladder Cancer, Ages ≥15 Years, Both Sexes, N, 2015
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Bladder Cancer, Ages ≥15 Years, N, 2015
  • Figure 10:7MM, Age-Standardized Diagnosed Incidence of Bladder Cancer (Cases per 100,000 Population), Ages ≥15 Years, Both Sexes, 2015
  • Figure 11: 7MM, Five-Year Diagnosed Prevalent Cases of Bladder Cancer, Ages ≥15 Years, Both Sexes, N, 2015-2025
  • Figure 12: NMIBC Treatment Algorithm
  • Figure 13: MIBC/Metastatic Disease Treatment Algorithm
  • Figure 14: Tecentriq's Development in Bladder Cancer
  • Figure 15: Opdivo's Development in Bladder Cancer
  • Figure 16: CG-0070's Development in Bladder Cancer
  • Figure 17: Instiladrin's Development in Bladder Cancer
  • Figure 18: Vicinium's Development in Bladder Cancer
  • Figure 19: Apatorsen's Development in Bladder Cancer
  • Figure 20: Cyramza's Development in Bladder Cancer
  • Figure 21: Avelumab's Development in Bladder Cancer
  • Figure 22: Durvalumab's Development in Bladder Cancer
  • Figure 23: Keytruda's Development in Bladder Cancer
  • Figure 24: Competitive Assessment of Marketed and Pipeline Agents in NMIBC, 2015-2025
  • Figure 25: Competitive Assessment of Marketed and Pipeline Agents in MIBC/Metastatic Disease, 2015-2025
  • Figure 26: Top-Line Sales for Bladder Cancer by Country/Region, 2015 and 2025
  • Figure 27: Global Sales for Bladder Cancer by Drug Class, 2015 and 2025
  • Figure 28: Sales for Bladder Cancer by Drug Class in the US, 2015 and 2025
  • Figure 29: Sales for Bladder Cancer by Drug Class in the 5EU, 2015 and 2025
  • Figure 30: Sales for Bladder Cancer by Drug Class in Japan, 2015 and 2025
Back to Top